These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 36693762)
21. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. Campbell MA; Wengel J Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437 [TBL] [Abstract][Full Text] [Related]
22. The Evolution of Antisense Oligonucleotide Chemistry-A Personal Journey. Agrawal S Biomedicines; 2021 May; 9(5):. PubMed ID: 34063675 [TBL] [Abstract][Full Text] [Related]
23. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics. Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636 [TBL] [Abstract][Full Text] [Related]
24. Advances in quantitative bioanalysis of oligonucleotide biomarkers and therapeutics. Wang L; Ji C Bioanalysis; 2016; 8(2):143-55. PubMed ID: 26652713 [TBL] [Abstract][Full Text] [Related]
25. [Study toward practical use of oligonucleotide therapeutics]. Inoue T; Yoshida T Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):13-5. PubMed ID: 25707197 [TBL] [Abstract][Full Text] [Related]
26. Antisense technology: an overview and prospectus. Crooke ST; Baker BF; Crooke RM; Liang XH Nat Rev Drug Discov; 2021 Jun; 20(6):427-453. PubMed ID: 33762737 [TBL] [Abstract][Full Text] [Related]
28. Delivery of oligonucleotides with lipid nanoparticles. Wang Y; Miao L; Satterlee A; Huang L Adv Drug Deliv Rev; 2015 Jun; 87():68-80. PubMed ID: 25733311 [TBL] [Abstract][Full Text] [Related]
29. Oligonucleotides as therapeutic tools for brain disorders: Focus on major depressive disorder and Parkinson's disease. Bortolozzi A; Manashirov S; Chen A; Artigas F Pharmacol Ther; 2021 Nov; 227():107873. PubMed ID: 33915178 [TBL] [Abstract][Full Text] [Related]
30. Liver as a target for oligonucleotide therapeutics. Sehgal A; Vaishnaw A; Fitzgerald K J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039 [TBL] [Abstract][Full Text] [Related]
31. Impurities in Oligonucleotide Drug Substances and Drug Products. Capaldi D; Teasdale A; Henry S; Akhtar N; den Besten C; Gao-Sheridan S; Kretschmer M; Sharpe N; Andrews B; Burm B; Foy J Nucleic Acid Ther; 2017 Dec; 27(6):309-322. PubMed ID: 29125795 [TBL] [Abstract][Full Text] [Related]
32. Is there a future for cell-penetrating peptides in oligonucleotide delivery? Lee SH; Castagner B; Leroux JC Eur J Pharm Biopharm; 2013 Sep; 85(1):5-11. PubMed ID: 23958313 [TBL] [Abstract][Full Text] [Related]
33. Recommendations of the Oligonucleotide Safety Working Group's Formulated Oligonucleotide Subcommittee for the Safety Assessment of Formulated Oligonucleotide-Based Therapeutics. Marlowe JL; Akopian V; Karmali P; Kornbrust D; Lockridge J; Semple S Nucleic Acid Ther; 2017 Aug; 27(4):183-196. PubMed ID: 28609186 [TBL] [Abstract][Full Text] [Related]
34. Recent advances in the medicinal chemistry of antisense oligonucleotides. Uhlmann E Curr Opin Drug Discov Devel; 2000 Mar; 3(2):203-13. PubMed ID: 19649851 [TBL] [Abstract][Full Text] [Related]
35. Applications of mass spectrometry to the study of siRNA. Beverly MB Mass Spectrom Rev; 2011; 30(6):979-98. PubMed ID: 20201110 [TBL] [Abstract][Full Text] [Related]